Skip to main content
. 2014 Jul;28(7):1166–1185. doi: 10.1210/me.2013-1403

Figure 1.

Figure 1.

Significance of PRMT2 in breast cancer A, Decreased mRNA expression of PRMT2 in breast cancer. PRMT2 mRNA expression level is presented in relative quantification with log2 scale from IDC human breast cancer tissue samples (n = 66) relative to normal breast tissue samples (n = 50). The nonparametric Wilcoxon rank sum test was conducted with the Integromics Statminer software package. For normalization, selected geNorm controls (MRPL19, PGK1, PPIA, TFRC, and UBC) were used. PRMT2 knockdown validation by RT-qPCR and Western blot analysis. B, MCF-7 cells were transfected with control-siRNA or PRMT2-siRNA (n = 6) for 48 hours. Relative gene expression level was determined for PRMT2 using Taqman gene expression assay (Applied Biosystems) normalized to an endogenous control (RPLP0). Data are presented as the mean (SEM) of six transfected cultures. C, Western blot analysis of whole-cell extracts collected after 72 hours of transfection with either control-siRNA or PRMT2-siRNA-1. D, PRMT2 isoforms were measured by RT-qPCR. Relative mRNA expression was determined using Sybr Green Assay and normalized to RPLP0. Data are presented as the mean (SEM) of three transfected cultures.